Core Insights - Zhejiang Haichang Biopharmaceutical Technology Co., Ltd. has completed nearly 500 million C-round financing, which will be used to advance nucleic acid drug pipeline research, develop new liver-targeted delivery systems, and enhance production capacity [1][2] Company Overview - Haichang Biopharmaceutical focuses on the core pain point of delivery systems in nucleic acid drug development, specializing in mRNA vaccines, small nucleic acid drugs, and high-end complex injectables [1] - The company has established an integrated industrial platform from research and development to commercialization since its founding [1] Technological Advancements - The company has developed the QTsome delivery platform, which breaks the patent monopoly of international pharmaceutical companies in lipid nanoparticle (LNP) delivery technology [2] - QTsome delivery platform allows for precise drug delivery and stable efficacy, adapting to various drugs for targeted treatment [2] Clinical Development - Haichang Biopharmaceutical's pipeline covers multiple important areas, including oncology, metabolic diseases, pain relief, and infectious diseases [2] - The small nucleic acid innovative drug HC0301 for primary liver cancer is currently undergoing multi-center Phase II clinical trials in China, Hong Kong, and the United States, leading the global field of small nucleic acid tumor precision therapy [2] Industry Ecosystem - The development of Haichang Biopharmaceutical is supported by the regional industrial ecosystem, particularly the establishment of the "Hangzhou Nucleic Acid Drug Valley" in the Hangzhou Pharmaceutical Port, which aims to position Zhejiang as a leader in global nucleic acid drug innovation [3]